Roche Holding AG (SWX:ROG)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 224.34B |
| Revenue (ttm) | 63.49B |
| Net Income (ttm) | 9.43B |
| Shares Out | 850.32M |
| EPS (ttm) | 11.74 |
| PE Ratio | 22.22 |
| Forward PE | 12.79 |
| Dividend | 9.70 (3.69%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 740,688 |
| Average Volume | 951,974 |
| Open | 261.20 |
| Previous Close | 262.60 |
| Day's Range | 259.20 - 262.00 |
| 52-Week Range | 231.90 - 313.80 |
| Beta | 0.17 |
| RSI | 56.44 |
| Earnings Date | Oct 20, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial StatementsNews
Roche's US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA
Basel, 25 August 2025 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today broke ground on its newest US manufacturing site in Holly Springs, North Carolina. This significant d...
Genentech and Roche Break Ground on State-of-the-Art Manufacturing Facility in Holly Springs, North Carolina
HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today broke ground on its newest U.S. manufacturing site in Holly Springs, North Carolina. Th...
“Walk in My Shoes” Spotlights the Invisible Struggles of People Living with Multiple Sclerosis (MS) – a Public Health Awareness Initiative by Roche in Collaboration with Multiple Sclerosis Society of India (MSSI)
Roche Pharma India, in collaboration with the Multiple Sclerosis Society of India (MSSI) presents Walk In My Shoes – a public health awareness initiative to highlight the often invisible struggles of ...
Global Ophthalmology Drugs Market to Reach USD 26.28 Billion by 2030 | MarketsandMarkets™
Delray Beach, FL, Aug. 18, 2025 (GLOBE NEWSWIRE) -- North America leads market expansion as companies advance next-generation ophthalmic therapies to address rising prevalence of vision-threatening di...
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
Topline results from the trial show that Signatera-positive patients treated with atezolizumab (Tecentriq®) had statistically significant and clinically meaningful improvements in disease-free surviva...
Pennsylvania Rep. Daniel Meuser Sold Up to $1.50M Worth of NVIDIA Stock
A August filing shows that Representative Daniel Meuser reported a sale in NVIDIA (NASDAQ: NVDA), valued between $750,002 and $1,500,000. The transaction date is listed as October 1, 2024, with the r...
Pilatus Biosciences Announces Clinical Trial Collaboration with Roche to Evaluate PLT012 in First-in-Human Study in Hepatocellular Carcinoma
EPALINGES, Switzerland--(BUSINESS WIRE)-- #HCC--Pilatus Biosciences Announces Clinical Trial Collaboration with Roche to Evaluate PLT012 in First-in-Human Study in Hepatocellular Carcinoma.
Roche, Novartis due to meet Swiss govt. amid Trump’s tariff threats: Reuters
Swiss government to meet pharma firms to discuss US tariffs
The Swiss government is due to meet this week with pharmaceuticals firms that U.S. President Donald Trump has asked to lower their prices, as Switzerland seeks to negotiate down a new 39% tariff on it...
Swiss Government Engages Roche and Novartis on U.S. Tariff Impact
Swiss Government Engages Roche and Novartis on U.S. Tariff Impact
Roche gets FDA clearance for respiratory test to detect viruses
Roche's Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)
Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III A...
Genentech's Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase II...
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Trump's pharmaceutical tariffs could affect some drugmakers more than others
AbbVie, Bristol Myers Squibb and Eli Lilly appear "relatively well-positioned," while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.
U.S. and European Union trade deal could cost the pharma industry up to $19 billion
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...
EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...
FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys
FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment. Latest Ratings ... Full story available on Benzinga.com
Roche presents new insights in Alzheimer's disease research across its diagnostics and pharmaceutical portfolios at AAIC
Basel, 28 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being presented at the Alzheimer's Association International Confer...
Genentech and Roche Present New Insights in Alzheimer's Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being pres...
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
Swiss drugmaker Roche Holding plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday.
Roche Holding AG 2025 Q2 - Results - Earnings Call Presentation
The following slide deck was published by Roche Holding AG in conjunction with their 2025 Q2 earnings call.
Roche Holding AG (RHHBY) Q2 2025 Earnings Call Transcript
Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy
On Friday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the conditional marketing authorisation (CMA) for Elevidys (del...